Sprout joins the ranks of biotech's biggest names following record-setting growth, expanding prescriber adoption, and increasing payer coverage RALEIGH, N.C., April 29, 2026 /PRNewswire/ -- TIME has ...

What Is Addyi, and Why Does It Matter? Addyi (flibanserin) is a nonhormonal prescription pill that is now approved by the FDA to treat low sexual desire in women younger than 65, including those who ...

The MarketWatch News Department was not involved in the creation of this content. Recognition follows Addyi's newly expanded FDA approval to treat both premenopausal and postmenopausal women under age ...

Viagra, the little blue pill, has been a household name for more than a generation. And now women's sexual health is finally entering the long-overdue conversation. The FDA recently approved the use ...

Up until now, women who’d surpassed menopause and were dealing with frustratingly low libido—a.k.a. hypoactive sexual desire disorder (HSDD)—had no dedicated treatment option available to them. But ...

The US Food and Drug Administration (FDA) has warned Sprout Pharmaceuticals for the second time concerning its promotion of its hypoactive sexual desire disorder (HSDD) drug Addyi. The agency also ...

Sprout Pharmaceuticals’ promotion of Addyi both mischaracterizes the drug’s indication and downplays potential serious adverse events associated with its use, according to a warning letter from the US ...

WASHINGTON -- The Food and Drug Administration on Tuesday approved the first prescription drug designed to boost sexual desire in women, a milestone long sought by a pharmaceutical industry eager to ...

RALEIGH, N.C., Jan. 29, 2026 /PRNewswire/ -- Sprout Pharmaceuticals today announced that Addyi® has been named "Best Prescription for Low Libido" in the 2026 Oprah Daily Menopause O-wards, one of the ...